院外心脏骤停患者初始72小时通气设置与结局的关系:TTM2试验预先计划的二次分析
该研究为TTM2试验的预先计划二次分析,纳入1848例院外心脏骤停后机械通气患者(平均年龄64岁,SD=14),描述入院最初72小时通气设置并分析其与6个月结局的关系。6个月时950例(51%)存活、898例(49%)死亡。中位潮气量7(IQR=6.2-8.5)mL/kg预测体重、PEEP 7(IQR=5-9)cmH2O、平台压20(IQR=17-23)cmH2O、驱动压12(IQR=10-15)cmH2O、机械功率16.2(IQR=12.1-21.8)J/min、通气比1.27(IQR=1.04-1.6)、呼吸频率17(IQR=14-20)次/分。呼吸频率、驱动压和机械功率与6个月死亡率独立相关(非线性轨迹omnibus P值分别为P<0.0001、P=0.026、P=0.029);呼吸频率和驱动压亦与神经功能不良独立相关(OR=1.035,95%CI=1.003-1.068,P=0.030;OR=1.005,95%CI=1.001-1.036,P=0.048)。作者认为最初72小时通气设置尤其是驱动压和呼吸频率可能影响6个月结局。
要点
- 院外心脏骤停后最初72小时的通气设置中,驱动压和呼吸频率与6个月死亡及神经功能不良独立相关。
- 呼吸频率与6个月神经功能不良相关:OR=1.035(95%CI=1.003-1.068,P=0.030)。
- 驱动压与6个月神经功能不良相关:OR=1.005(95%CI=1.001-1.036,P=0.048)。
- 呼吸频率、驱动压和机械功率与6个月死亡率独立相关,非线性轨迹omnibus P值分别为P<0.0001、P=0.026、P=0.029。
- 复合公式[(4×驱动压)+呼吸频率]与死亡率和神经功能不良独立相关。
适用人群与场景
- 院外心脏骤停后接受机械通气的患者,纳入TTM2试验并进入本预先计划二次分析的1848例,平均年龄64岁(SD=14)。
研究设计与关键结果
- 研究类型:TTM2试验的预先计划二次分析;样本量1848例;人群为院外心脏骤停后机械通气患者,平均年龄64岁(SD=14)。
- 6个月时950例(51%)存活,898例(49%)死亡。
- 最初72小时通气参数中位数:潮气量7(IQR=6.2-8.5)mL/kg预测体重,PEEP 7(IQR=5-9)cmH2O,平台压20(IQR=17-23)cmH2O,驱动压12(IQR=10-15)cmH2O,机械功率16.2(IQR=12.1-21.8)J/min,通气比1.27(IQR=1.04-1.6),呼吸频率17(IQR=14-20)次/分;氧分压中位数87 mmHg(IQR=75-105),二氧化碳分压中位数40.5 mmHg(IQR=36-45.7)。
- 呼吸频率、驱动压和机械功率与6个月死亡率独立相关,非线性轨迹omnibus P值分别为P<0.0001、P=0.026、P=0.029。
- 呼吸频率与神经功能不良独立相关:OR=1.035(95%CI=1.003-1.068,P=0.030);驱动压与神经功能不良独立相关:OR=1.005(95%CI=1.001-1.036,P=0.048)。
- 复合公式[(4×驱动压)+呼吸频率]与死亡率和神经功能不良独立相关。
证据类型、等级与局限
- 证据类型:随机对照试验TTM2的预先计划二次分析;局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,入院后最初72小时的通气设置,尤其是驱动压和呼吸频率,可能影响院外心脏骤停患者的6个月结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: The optimal ventilatory settings in patients after cardiac arrest and their association with outcome remain unclear. The aim of this study was to describe the ventilatory settings applied in the first 72 h of mechanical ventilation in patients after out-of-hospital cardiac arrest and their association with 6-month outcomes.
METHODS: Preplanned sub-analysis of the Target Temperature Management-2 trial. Clinical outcomes were mortality and functional status (assessed by the Modified Rankin Scale) 6 months after randomization.
RESULTS: A total of 1848 patients were included (mean age 64 [Standard Deviation, SD = 14] years). At 6 months, 950 (51%) patients were alive and 898 (49%) were dead. Median tidal volume (VT) was 7 (Interquartile range, IQR = 6.2-8.5) mL per Predicted Body Weight (PBW), positive end expiratory pressure (PEEP) was 7 (IQR = 5-9) cmH20, plateau pressure was 20 cmH20 (IQR = 17-23), driving pressure was 12 cmH20 (IQR = 10-15), mechanical power 16.2 J/min (IQR = 12.1-21.8), ventilatory ratio was 1.27 (IQR = 1.04-1.6), and respiratory rate was 17 breaths/minute (IQR = 14-20). Median partial pressure of oxygen was 87 mmHg (IQR = 75-105), and partial pressure of carbon dioxide was 40.5 mmHg (IQR = 36-45.7). Respiratory rate, driving pressure, and mechanical power were independently associated with 6-month mortality (omnibus p-values for their non-linear trajectories: p < 0.0001, p = 0.026, and p = 0.029, respectively). Respiratory rate and driving pressure were also independently associated with poor neurological outcome (odds ratio, OR = 1.035, 95% confidence interval, CI = 1.003-1.068, p = 0.030, and OR = 1.005, 95% CI = 1.001-1.036, p = 0.048). A composite formula calculated as [(4*driving pressure) + respiratory rate] was independently associated with mortality and poor neurological outcome.
CONCLUSIONS: Protective ventilation strategies are commonly applied in patients after cardiac arrest. Ventilator settings in the first 72 h after hospital admission, in particular driving pressure and respiratory rate, may influence 6-month outcomes.
参考来源
- Robba C, Badenes R, Battaglini D, et al. Ventilatory settings in the initial 72 h and their association with outcome in out-of-hospital cardiac arrest patients: a preplanned secondary analysis of the targeted hypothermia versus targeted normothermia after out-of-hospital cardiac arrest (TTM2) trial. Intensive Care Med. 2022. PMID: 35780195. doi:10.1007/s00134-022-06756-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。